Your browser is no longer supported. Please, upgrade your browser.
Settings
BPMC Blueprint Medicines Corporation daily Stock Chart
BPMC [NASD]
Blueprint Medicines Corporation
Index- P/E- EPS (ttm)-6.08 Insider Own0.10% Shs Outstand48.98M Perf Week12.28%
Market Cap4.74B Forward P/E- EPS next Y-7.99 Insider Trans-70.61% Shs Float47.68M Perf Month27.53%
Income-267.50M PEG- EPS next Q-1.84 Inst Own95.00% Short Float4.91% Perf Quarter16.07%
Sales44.30M P/S106.99 EPS this Y-37.60% Inst Trans6.69% Short Ratio4.43 Perf Half Y73.77%
Book/sh7.81 P/B12.39 EPS next Y-3.50% ROA-45.40% Target Price109.38 Perf Year42.69%
Cash/sh8.49 P/C11.40 EPS next 5Y34.00% ROE-59.30% 52W Range44.58 - 100.76 Perf YTD79.50%
Dividend- P/FCF- EPS past 5Y-42.40% ROI-59.00% 52W High-3.96% Beta1.48
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low117.09% ATR4.64
Employees239 Current Ratio6.60 Sales Q/Q-30.00% Oper. Margin- RSI (14)66.85 Volatility4.35% 5.10%
OptionableYes Debt/Eq0.00 EPS Q/Q-53.20% Profit Margin- Rel Volume1.49 Prev Close97.80
ShortableYes LT Debt/Eq0.00 EarningsMay 09 BMO Payout- Avg Volume528.57K Price96.77
Recom1.40 SMA2014.42% SMA5019.88% SMA20034.90% Volume789,845 Change-1.05%
May-23-19Resumed Goldman Buy $125
Apr-03-19Initiated Morgan Stanley Overweight $112
Sep-25-18Initiated Leerink Partners Outperform
Dec-11-17Reiterated Goldman Buy $82 → $99
Sep-29-17Initiated BTIG Research Buy $90
Apr-05-17Reiterated Wedbush Outperform $43 → $50
Mar-13-17Upgrade Goldman Neutral → Buy
Feb-15-17Initiated Morgan Stanley Overweight
Dec-14-16Initiated Jefferies Buy $40
May-27-16Initiated Raymond James Outperform $23
May-26-15Initiated Wedbush Outperform
May-26-15Initiated JMP Securities Mkt Outperform $54
May-26-15Initiated Goldman Neutral $26
Jun-19-19 11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
Jun-18-19 09:51AM  Cancer Therapy Stocks Soar After Pfizer Deal Investopedia
07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-15-19 06:00AM  Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress PR Newswire
Jun-14-19 06:09PM  Edited Transcript of BPMC earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
08:45AM  Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST PR Newswire
Jun-10-19 09:39AM  Hedge Funds Have Never Been This Bullish On Blueprint Medicines Corporation (BPMC) Insider Monkey
Jun-08-19 09:30AM  Blueprint Medicines (BPMC) Up 7.3% Since Last Earnings Report: Can It Continue? Zacks
Jun-06-19 09:17AM  Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals +8.41%
Jun-05-19 11:44AM  Blueprint Medicines to File NDA for Avapritinib With FDA Zacks +5.96%
Jun-03-19 04:24PM  Who Are The Winners And Losers From The Year's Biggest Cancer Meeting? Investor's Business Daily
10:26AM  Blueprint Medicines' NDA for Avapritinib on Track for GIST Zacks
09:00AM  Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019 PR Newswire
Jun-01-19 09:00AM  Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib PR Newswire
May-29-19 04:00PM  Blueprint Medicines to Present at Upcoming Investor Conferences in June PR Newswire
May-23-19 07:26PM  2 Top Stocks to Watch at ASCO 2019 Motley Fool
May-16-19 09:00AM  Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations PR Newswire +5.04%
May-15-19 10:16AM  3 Stocks With Big News Coming at ASCO 2019 Motley Fool
May-14-19 11:12AM  How Much is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Getting Paid? Simply Wall St.
May-13-19 08:44AM  Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates Zacks -11.34%
May-10-19 08:24AM  Blueprint Medicines (BPMC) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 08:35AM  Blueprint Medicines (BPMC) Reports Q1 Loss, Misses Revenue Estimates Zacks +7.22%
07:23AM  Blueprint Medicines: 1Q Earnings Snapshot Associated Press
07:00AM  Blueprint Medicines Reports First Quarter 2019 Financial Results PR Newswire
May-08-19 10:38AM  Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More Zacks
08:00AM  Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference PR Newswire
May-02-19 08:00AM  Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019 PR Newswire
Apr-29-19 12:59PM  Did Hedge Funds Drop The Ball On Blueprint Medicines Corporation (BPMC) ? Insider Monkey
Apr-24-19 10:33AM  Earnings Preview: Blueprint Medicines (BPMC) Q1 Earnings Expected to Decline Zacks
Apr-03-19 08:16AM  3 Small-Cap Biotech Stocks to Watch Now Motley Fool
Apr-02-19 04:01PM  Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock PR Newswire
Apr-01-19 08:43AM  Blueprint Medicines (BPMC) Looks Good: Stock Adds 5.7% in Session Zacks
Mar-30-19 10:12AM  If You Had Bought Blueprint Medicines (NASDAQ:BPMC) Stock Three Years Ago, You Could Pocket A 337% Gain Today Simply Wall St.
Mar-28-19 08:40PM  Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock PR Newswire -5.22%
11:18AM  Blueprint Medicines Expediates Filings for Key Candidates Zacks
Mar-27-19 04:03PM  Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock PR Newswire
04:00PM  Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress PR Newswire
02:47PM  5 Cancer-Fighting Stocks to Boost Portfolio Gains Zacks
Mar-23-19 12:14PM  3 Cancer Treatment Stocks to Buy in March Motley Fool
Mar-05-19 08:01AM  Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference PR Newswire
Mar-01-19 07:10AM  Market Trends Toward New Normal in ITT, Palo Alto Networks, Enterprise Products Partners, Blueprint Medicines, Lincoln Electric, and NewMarket Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire +5.37%
06:52AM  Edited Transcript of BPMC earnings conference call or presentation 26-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-26-19 01:16PM  Blueprint Medicines Corp (BPMC) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Feb-21-19 04:00PM  3 Top Healthcare Stocks to Buy in February Motley Fool
Feb-19-19 08:00AM  Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019 PR Newswire
Feb-13-19 10:31AM  Earnings Preview: Blueprint Medicines (BPMC) Q4 Earnings Expected to Decline Zacks
Feb-07-19 04:01PM  Blueprint Medicines to Present at Upcoming Investor Conferences in February PR Newswire
Jan-24-19 09:00AM  Three Companies Using AI and Innovation to Lead Healthcare Sector ACCESSWIRE
Jan-22-19 04:40PM  Edited Transcript of BPMC earnings conference call or presentation 30-Oct-18 12:30pm GMT Thomson Reuters StreetEvents
Jan-17-19 03:50PM  Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table Investor's Business Daily
Jan-07-19 03:47PM  Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today Motley Fool +14.14%
03:06PM  Cancer stocks heat up after third big merger in the past month MarketWatch
Jan-04-19 08:00AM  Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals PR Newswire +9.82%
Dec-17-18 07:20AM  Analysis: Positioning to Benefit within Quidel, Granite Construction, FireEye, Consolidated Edison, EnPro Industries, and Blueprint Medicines Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-08-18 11:33AM  Is Blueprint Medicines Corporation (BPMC) A Good Stock To Buy? Insider Monkey
Dec-04-18 12:14PM  Is Blueprint Medicines Corporations (NASDAQ:BPMC) CEO Overpaid Relative To Its Peers? Simply Wall St.
Dec-02-18 12:30PM  Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis PR Newswire
Nov-15-18 07:00AM  Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy PR Newswire -6.98%
Nov-05-18 07:40AM  Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-30-18 08:50AM  Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:44AM  Blueprint Medicines: 3Q Earnings Snapshot Associated Press
07:00AM  Blueprint Medicines Reports Third Quarter 2018 Financial Results PR Newswire
Oct-29-18 04:01PM  Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International PR Newswire -5.82%
Oct-23-18 04:01PM  Blueprint Medicines to Report Third Quarter 2018 Financial Results on Tuesday, October 30, 2018 PR Newswire
10:32AM  Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For Zacks
Oct-08-18 08:20AM  Report: Exploring Fundamental Drivers Behind Masonite International, Chart Industries, Blueprint Medicines, Cross Country Healthcare, HNI, and Paylocity Holding New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-06-18 08:50AM  Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers PR Newswire
Oct-01-18 08:00AM  Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva PR Newswire -5.34%
Sep-26-18 08:00AM  Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion PR Newswire
Sep-24-18 08:00AM  Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings PR Newswire
Sep-05-18 08:00AM  Blueprint Medicines to Present at 16th Annual Morgan Stanley Global Healthcare Conference PR Newswire
Aug-03-18 09:20AM  Edited Transcript of BPMC earnings conference call or presentation 1-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 06:31AM  What Blueprint Medicines Just Said About Its Future Motley Fool +5.11%
Aug-01-18 04:01PM  Blueprint Medicines to Present at Upcoming Investor Conferences in August PR Newswire +12.18%
08:35AM  Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:34AM  Blueprint Medicines: 2Q Earnings Snapshot Associated Press
07:00AM  Blueprint Medicines Reports Second Quarter 2018 Financial Results PR Newswire
06:30AM  Blueprint Medicines Corp. to Host Earnings Call ACCESSWIRE
Jul-25-18 08:00AM  Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018 PR Newswire
Jun-21-18 08:30AM  New Research: Key Drivers of Growth for Illinois Tool Works, Aircastle, TriState Capital, Blueprint Medicines, MGE Energy, and Cubic Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
08:00AM  Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors PR Newswire
Jun-15-18 08:00AM  Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity PR Newswire -7.29%
Jun-06-18 07:40AM  Blog Exposure - Blueprint Medicines Signed Collaboration Deal with CStone Pharma to Develop and Commercialize Avapritinib, BLU-554, and BLU-667 in Greater China ACCESSWIRE -5.23%
Jun-04-18 04:23PM  Why #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% Today Motley Fool -9.24%
02:06PM  Blueprint Medicines CEO on genetic targeting for cancer CNBC Videos
07:00AM  Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China PR Newswire
Jun-02-18 10:17AM  Loxo Scores A Success With Second Targeted Cancer Drug Forbes
Jun-01-18 04:40PM  Conquering cancer in the Windy City CNBC Videos
May-31-18 06:01PM  The Big Thing to Watch at ASCO 2018 Motley Fool
08:30AM  Free Technical Insights on CASI Pharma and Three Other Biotech Stocks ACCESSWIRE
08:00AM  Blueprint Medicines to Present at Upcoming Investor Conferences in June PR Newswire
May-25-18 03:00AM  Blueprint Medicines Shows Market Leadership With Jump To 93 RS Rating Investor's Business Daily
May-24-18 12:41PM  Blueprint CEO traces biotech's rapid growth at opening of new HQ American City Business Journals
May-17-18 09:00AM  Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis PR Newswire -5.19%
May-07-18 11:55PM  Edited Transcript of BPMC earnings conference call or presentation 2-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-02-18 08:24AM  Blueprint Medicines: 1Q Earnings Snapshot Associated Press
07:00AM  Blueprint Medicines Reports First Quarter 2018 Financial Results PR Newswire
06:30AM  Blueprint Medicines Corp. to Host Earnings Call ACCESSWIRE
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hurley ArielPrincipal Accounting OfficerJun 13Option Exercise1.871,6603,1041,660Jun 14 06:01 PM
Hurley ArielPrincipal Accounting OfficerJun 13Sale90.001,660149,4000Jun 14 06:01 PM
Demetri GeorgeDirectorJun 13Sale90.0056851,1205,871Jun 17 05:12 PM
Lydon NicholasDirectorJun 13Sale90.3625,0002,259,000127,727Jun 17 05:11 PM
Albers Jeffrey W.CEO and PresidentJun 12Option Exercise1.8720,00037,40048,961Jun 14 06:00 PM
Hurley ArielPrincipal Accounting OfficerJun 12Option Exercise1.878301,552830Jun 14 06:01 PM
Hurley ArielPrincipal Accounting OfficerJun 12Sale85.001,07391,2050Jun 14 06:01 PM
Lydon NicholasDirectorJun 12Sale84.7725,0002,119,162152,727Jun 14 06:00 PM
Albers Jeffrey W.CEO and PresidentJun 12Sale84.7520,0001,694,90628,961Jun 14 06:00 PM
Hurley ArielPrincipal Accounting OfficerMar 15Option Exercise1.87415776415Mar 19 05:23 PM
Albers Jeffrey W.CEO and PresidentMar 15Option Exercise1.8720,00037,40048,961Mar 19 05:25 PM
Albers Jeffrey W.CEO and PresidentMar 15Sale86.3920,0001,727,88428,961Mar 19 05:25 PM
Hurley ArielPrincipal Accounting OfficerMar 15Sale85.5541535,5030Mar 19 05:23 PM
Dorsch MarionChief Scientific OfficerMar 04Option Exercise37.112,30085,3532,300Mar 06 05:04 PM
Dorsch MarionChief Scientific OfficerMar 04Sale84.662,300194,7230Mar 06 05:04 PM
Haviland KateChief Operating OfficerMar 01Option Exercise23.1321,644500,63927,518Mar 05 05:31 PM
Haviland KateChief Operating OfficerMar 01Sale85.0521,6441,840,8225,874Mar 05 05:31 PM
Albers Jeffrey W.CEO and PresidentNov 19Option Exercise1.8728,96154,15728,961Nov 21 07:20 AM
Albers Jeffrey W.CEO and PresidentNov 05Option Exercise1.8720,00037,40020,000Nov 07 04:25 PM
Albers Jeffrey W.CEO and PresidentNov 05Sale63.4920,0001,269,7090Nov 07 04:25 PM
Dorsch MarionChief Scientific OfficerSep 17Option Exercise37.112,30085,3532,300Sep 19 04:08 PM
Dorsch MarionChief Scientific OfficerSep 17Sale70.472,300162,0920Sep 19 04:08 PM
Albers Jeffrey W.CEO and PresidentAug 06Option Exercise1.8720,00037,40020,000Aug 08 04:08 PM
Albers Jeffrey W.CEO and PresidentAug 06Sale70.5920,0001,411,8960Aug 08 04:08 PM